Introduction Autoimmune pancreatitis (AIP) is a unique IgG4-related inflammatory disease with generally favourable outcomes following glucocorticoid therapy. However, beyond pancreatic inflammation, extension into the peripancreatic vasculature can occur, leading to venous stenosis, collateral formation, and in severe cases, gastric varices.
Introduction
Autoimmune pancreatitis (AIP) is a unique IgG4-related inflammatory disease with generally favourable outcomes following glucocorticoid therapy. However, beyond pancreatic inflammation, extension into the peripancreatic vasculature can occur, leading to venous stenosis, collateral formation, and in severe cases, gastric varices. These vascular complications remain underrecognized and are not adequately addressed in existing diagnostic guidelines, despite their potential to cause life-threatening bleeding.
Problem Statement
There is limited large-scale evidence on the true prevalence, clinical significance, and treatment responsiveness of peripancreatic vascular involvement in AIP. Additionally, there is no clear strategy to identify patients at risk of gastric varices or variceal rupture, leading to potential missed opportunities for early intervention.
Summary
This multicenter Japanese study demonstrates that peripancreatic vascular involvement is common in AIP, occurring in over 50% of patients, most frequently affecting the splenic vein. Collateral formation was observed in 40%, and gastric varices were identified in approximately 11% of those undergoing endoscopy, with rare but serious cases of variceal rupture. Importantly, glucocorticoid therapy showed excellent efficacy, reversing venous stenosis in more than 90% of cases and improving collateral circulation in the majority. Severe splenic vein involvement emerged as a key predictor of gastric varices. These findings highlight the need for routine vascular assessment in AIP and selective endoscopic screening in high-risk patients to prevent fatal complications.
Introduction: Advanced biliary tract cancer (BTC) carries a poor prognosis, with limited improvements in survival despite the addition of immune checkpoint inhibitors to standard gemcitabine–cisplatin chemotherapy. This phase II trial evaluated ivonescimab, a novel PD-1/VEGF...
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a cornerstone in the management of type 2 diabetes because of their excellent glycemic, cardiovascular, and weight-loss benefits. However, concerns remain regarding their potential association with...
Introduction: Patients undergoing pancreatoduodenectomy for non invasive intraductal papillary mucinous neoplasm (IPMN) require long-term surveillance because of the risk of disease recurrence in the pancreatic remnant. New pancreatic duct (PD) dilatation is commonly detected during...
• This study evaluated 1,063 patients undergoing pancreatic surgery; 11% developed conventionally defined chyle leak. • Most clinically relevant cases were grade B, while no grade C leaks were reported. • A minimally invasive surgical...
Introduction: Endoscopic ultrasound (EUS)-guided drainage has become the preferred minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Fatty pancreas disease (FPD), also known as intrapancreatic fat deposition, has emerged as an important metabolic condition closely linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Although ectopic fat accumulation in...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.